- Home
- EXEL vs LBRDA Comparison
EXEL vs LBRDA Comparison
Compare EXEL & LBRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- LBRDA
- Stock Information
- Founded
- EXEL 1994
- LBRDA 2014
- Country
- EXEL United States
- LBRDA United States
- Employees
- EXEL N/A
- LBRDA N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- LBRDA Cable & Other Pay Television Services
- Sector
- EXEL Health Care
- LBRDA Telecommunications
- Exchange
- EXEL Nasdaq
- LBRDA Nasdaq
- Market Cap
- EXEL 9.4B
- LBRDA 11.2B
- IPO Year
- EXEL 2000
- LBRDA N/A
- Fundamental
- Price
- EXEL $37.42
- LBRDA $85.19
- Analyst Decision
- EXEL Buy
- LBRDA Buy
- Analyst Count
- EXEL 18
- LBRDA 2
- Target Price
- EXEL $37.59
- LBRDA $83.50
- AVG Volume (30 Days)
- EXEL 2.8M
- LBRDA 108.6K
- Earning Date
- EXEL 04-29-2025
- LBRDA 05-07-2025
- Dividend Yield
- EXEL N/A
- LBRDA N/A
- EPS Growth
- EXEL 170.77
- LBRDA 29.85
- EPS
- EXEL 1.76
- LBRDA 6.08
- Revenue
- EXEL $2,168,701,000.00
- LBRDA $1,016,000,000.00
- Revenue This Year
- EXEL $5.45
- LBRDA $3.15
- Revenue Next Year
- EXEL $10.32
- LBRDA $1.15
- P/E Ratio
- EXEL $21.43
- LBRDA $14.05
- Revenue Growth
- EXEL 18.50
- LBRDA 3.57
- 52 Week Low
- EXEL $20.14
- LBRDA $47.17
- 52 Week High
- EXEL $40.02
- LBRDA $100.44
- Technical
- Relative Strength Index (RSI)
- EXEL 58.85
- LBRDA 59.87
- Support Level
- EXEL $36.68
- LBRDA $80.02
- Resistance Level
- EXEL $37.99
- LBRDA $85.10
- Average True Range (ATR)
- EXEL 1.09
- LBRDA 2.44
- MACD
- EXEL -0.11
- LBRDA 0.08
- Stochastic Oscillator
- EXEL 49.87
- LBRDA 61.37
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About LBRDA Liberty Broadband Corporation
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential and small to medium businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.